Neuropeptide Y and leptin in patients with obstructive sleep apnea syndrome: Role of obesity

American Journal of Respiratory and Critical Care Medicine

Volumn 171, Issue 2, 2005, Pages 183-187

  Barceló, Antonia ^b   Barbé, Ferran ^a   Llompart, Elena ^b   De La Peña, Mónica ^b   Durán Cantolla, Joaquin ^b   Ladaria, Antoni ^b   Bosch, Margalida ^b   Guerra, Lourdes ^b   Agustí, Alvar G N ^b  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b NONE

Author keywords

Cardiovascular risk; Continuous positive airway pressure; Obesity; Sympathetic nervous system

Indexed keywords

LEPTIN; NEUROPEPTIDE Y;

ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENERGY BALANCE; HUMAN; MALE; OBESITY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SLEEP APNEA SYNDROME; SYMPATHETIC TONE;

ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CONTINUOUS POSITIVE AIRWAY PRESSURE; HUMANS; LEPTIN; MALE; MIDDLE AGED; NEUROPEPTIDE Y; OBESITY; PROSPECTIVE STUDIES; SLEEP APNEA, OBSTRUCTIVE; STATISTICS, NONPARAMETRIC;

EID: 12144260547     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200405-579OC     Document Type: Article

References (34)

1. Douglas NJ, Polo O. Pathogenesis of sleep apnoea/hypopnoea syndrome. Lancet 1994;344:653-655.
2. Brown LK. A waist is a terrible thing to mind: central obesity, the metabolic syndrome, and sleep apnea hypopnea syndrome. Chest 2002;122:774-778.
3. Phillips BG, Kato M, Narkiewicz K, Choe I, Somers VK. Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea. Am J Physiol Heart Circ Physiol 2000;279:H234-H237.
4. Chin K, Shimizu K, Nakamura T, Narai N, Masuzaki H, Ogawa Y, Mishima M, Nakamura T, Nakao K, Ohi M. Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. Circulation 1999;100:706-712.
5. Shimizu K, Chin K, Nakamura T, Masuzaki H, Ogawa Y, Hosokawa R, Niimi A, Hattori N, Nohara R, Sasayama S, et al. Plasma leptin levels and cardiac sympathetic function in patients with obstructive sleep apnoea-hypopnoea syndrome. Thorax 2002;57:429-434.
6. Flier JS. Maratos-Flier E. Obesity and the hypothalamus: novel peptides for new pathways. Cell 1998;92:437-440.
7. Mark AL, Correia M, Morgan DA, Shaffer RA, Haynes WG. Obesity-induced hypertension: new concepts from the emerging biology of obesity. Hypertension 1999;33:537-541.
8. Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens 2001;14:103S-115S.
9. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230-1235.
10. Rajala R, Partinen M, Sane T, Pelkonen R, Huikuri K, Seppalainen AM. Obstructive sleep apnoea syndrome in morbidly obese patients. J Intern Med 1991;230:125-129.
11. Matsumura K, Tsuchihashi T, Abe I. Central cardiovascular action of neuropeptide Y in conscious rabbits. Hypertension 2000;36:1040-1044.
12. Aizawa-Abe M, Ogawa Y, Masuzaki H, Ebihara K, Satoh N, Iwai H, Matsuoka N, Hayashi T, Hosoda K, Inove G, et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000;105:1243-1252.
13. Friedman J, Halaas J. Leptin and the regulation of body weight in mammals. Nature 1998;395:763-770.
14. Stanley BG. Neuropeptide Y in multiple hypothalamic sites control eating behavior, endocrine and autonomic systems for energy balance. In: Colmers WF, Wahlestedt C, editors. The biology of neuropeptide Y and related peptides. Totowa, NJ: Humana Press; 1993. pp. 457-509.
15. Lonnquist F, Arner P, Nordfors L, Schalling M. Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. Nat Med 1995;1:950-953.
16. Ip MSM, Lam KSL, Ho C, Tsang KWT, Lam W. Serum leptin and vascular risk factors in obstructive sleep apnea. Chest 2000;118:580-586.
17. Carlson JA, Hedner JA, Elam M, Ejnell H, Sellgren J, Gunar Wallin B. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest 1993;103:1763-1768.
18. Barcelo A, Barbe F, Llompart E, Mayoralas LR, Vila M, Ladaria A, Bosch M, Agusti AGN. Influencia de la obesidad en los niveles plasmáticos de neuropéptido Y en pacientes con SAS [abstract]. Arch Bronconeumol 2002;38:21.
19. Montserrat JM, Amilibia J, Barbe F, Capote F, Duran J, Mangado NG, Jimenez A, Marin JM, Masa F, Teran J. Tratamiento del síndrome de las apneas-hipoapneas durante el sueño. Arch Bronconeumol 1998;24:206-208.
20. U.S. Public Health Service. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. Bethesda, MD; 1998. National Institutes of Health Publication No. 98-4083.
21. Barcelo A, Barbe F, Llompart E, Mayoralas LR, Ladaria A, Bosch M, Agusti AGN. Effects of obesity on C-reactive protein level and metabolic disturbances in male patients with obstructive sleep apnea. Am J Med 2004;117:118-121.
22. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-545.
23. Carrera M, Barbe F, Agusti AGN. Does the number of hypopnoeas influence therapy in patients with obstructive sleep apnoea? Respir Med 1998;92:1028-1031.
24. Perloff D, Grim C, Flack J. Frohlich ED, Hill M, McDonald M, Morgensterm BZ. Human blood pressure determination by sphygmomanometry. Circulation 1993;88:2460-2470.
25. Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin HM. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance and hypercytokinemia. J Clin Endocrinol Metab 2000;85:1151-1158.
26. Zukowska-Grojec Z, Wahlestedtt C. Origin and actions of neuropeptide Y in the cardiovascular system. In: Colmers WF, Wahlestedt C, editors. The biology of neuropeptide Y and related peptides. Totowa, NJ: Humana Press; 1993. pp. 315-388.
27. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, Yeh Y, Chen WT, Kleinman HK, Grouzmann E. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 1998;83:187-195.
28. Gullestad L, Jorgensen B, Thorvald B, Pernow J, Lundberg JM, Dota CD, Hall C, Simonsen S, Ablad B. Postexercise ischemia is associated with increased neuropeptide Y in patients with coronary artery disease. Circulation 2000;102:987-993.
29. Malmstrom RE. Pharmacology of neuropeptide Y receptor antagonists: focus on cardiovascular functions. Eur J Pharmacol 2002;447:11-30.
30. Kaijser L, Pernow J, Berglund B, Grubbstrom J, Lundberg JM. Neuropeptide Y release from human heart is enhanced during prolonged exercise in hypoxia. J Appl Physiol 1994;76:1346-1349.
31. Kask A, Harro J, von horsten S, Redrobe JP, Dumont Y, Quirion R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci Biobehav Rev 2002;26:259-283.
32. Harsch IA, Konturek PC, Koebnick C, Kuehnlein PP, Fuchs FS, Pour Schahin S, Wiest GH. Hahn EG, Lohmann T, Ficker JH. Leptin and ghrelin levels in patients with obstructive sleep apnea. Eur Respir J 2003;22:251-257.
33. Schäfer H, Pauleit D, Sudhop T, Gouni-Berthold I, Ewig S, Berthold HK. Body fat distribution, serum leptin, and cardiovascular risk factors in men with obstructive sleep apnea. Chest 2002;122:829-839.
34. Sanner BM, Kollhosser P, Buechner N, Zidek W, Tepel M. Influence of treatment on leptin levels in patients with obstructive sleep apnoea. Eur Respir J 2004;23:601-604.